Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes

被引：1

作者：

Hirata, Takumi ^{[1
]}

Inukai, Kouichi ^{[2
]}

Morimoto, Jiro ^{[3
]}

Katayama, Shigehiro ^{[4
]}

Ishida, Hitoshi ^{[2
]}

机构：

[1] Fdn Biomed Res & Innovat, Kobe, Hyogo 6500047, Japan

[2] Kyorin Univ, Sch Med, Dept Internal Med 3, Tokyo, Japan

[3] Saitama Social Insurance Hosp, Dept Internal Med, Saitama, Japan

[4] Saitama Med Univ, Sch Med, Dept Endocrinol & Diabet, Saitama, Japan

来源：

PRIMARY CARE DIABETES | 2014年 / 8卷 / 03期

关键词：

Sitagliptin; Glycemic control; Concomitant drugs; Type; 2; diabetes; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; EFFICACY; SAFETY; SECRETION; MIGLITOL;

D O I：

10.1016/j.pcd.2014.01.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims: We investigated to clarify factors associated with the efficacy of sitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor, for glycemic control including the confounding effect of concomitant drugs in patients with type 2 diabetes. Methods: We included type 2 diabetes patients with HbA1c levels of >= 7% who were not under insulin treatment and were administered sitagliptin (50 mg/day for 6 months). Reduction or discontinuation of insulin sensitizers was not permitted during the study period. Outcomes included HbA1c level variations and attaining a target HbA1c level of <7%. Associated factors with each outcome were examined using multivariate analysis. Results: Of the 313 patients enrolled in this study, 147 (47.0%) attained HbA1c levels of <7%. High baseline HbA1c levels were associated with HbA1c level variations but inversely associated with attaining the target HbA1c level of <7%. Concomitant use of an insulin sensitizer and a alpha-glucosidase inhibitor and maintenance of the baseline dose of concomitant drugs were significantly associated with each outcome. Conclusions: Our results suggest that concomitant sitagliptin administration (50 mg/day) will improve glycemic control if treatment is initiated before HbA1c levels deteriorate. Other medication should be continued at initiation of sitagliptin administration. (C) 2014 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

引用

页码：265 / 270

页数：6